S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

NexImmune (NEXI) Earnings Date, Estimates & Call Transcripts

$3.15
-0.32 (-9.22%)
(As of 04/17/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

NEXI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NEXI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

NEXI Earnings Date and Information

NexImmune has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off prior year's report dates.

NexImmune Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/20/2024
Estimated)
------- 
11/17/2023Q3 2023-($9.40)($9.40)($9.40)--
8/10/2023Q2 2023($7.25)($7.25)-($0.29)--
5/15/2023Q1 2023($11.25)($9.25)+$2.00($0.37)--
3/28/2023Q4 2022($14.50)($16.25)($1.75)($0.65)--
11/14/2022Q3 2022($16.50)($15.00)+$1.50($0.60)--
8/15/2022Q2 2022($16.50)($17.25)($0.75)($0.69)--
5/12/2022Q1 2022($17.75)($16.50)+$1.25($0.66)--    
3/9/2022Q4 2021($21.00)($17.00)+$4.00($0.68)--
11/12/2021Q3 2021($16.75)($16.25)+$0.50($0.65)--
8/9/2021Q2 2021($13.50)($13.50)-($0.54)--
5/17/2021Q1($16.5750)($17.75)($1.1750)($0.71)--

NexImmune Earnings - Frequently Asked Questions

When is NexImmune's earnings date?

NexImmune has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off last year's report dates. Learn more on NEXI's earnings history.

How much profit does NexImmune generate each year?

NexImmune (NASDAQ:NEXI) has a recorded net income of -$62.51 million. NEXI has generated -$42.15 earnings per share over the last four quarters.


More Earnings Resources from MarketBeat

This page (NASDAQ:NEXI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners